| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.2 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |